How AI is applied across API Evangelist and APIs.io. Read my AI disclosure →
API Evangelist API Evangelist
Discovery
Learnings
Guidance
Toolbox
Alignment
API Evangelist LLC

Electra Therapeutics Announces Initiation of a Phase 1 Trial of ELA822, a Novel SIRPγ-Specific Antibody Designed to Treat T Cell-Mediated Immune and Inflammatory Diseases

calendar_today September 10, 2026 person kim Nguyen domain electra-therapeutics

SOUTH SAN FRANCISCO, CA, Sept. 10, 2026 – Electra Therapeutics, a clinical-stage biopharmaceutical company focused on pioneering a new class of precision medicines for the treatment of immune-mediated diseases and cancer, today announced the initiation of a Phase 1…

open_in_new Read original post